GlassScriptPhysician profile
Manuel A Macapinlac
NPI 1811975345
$1,602.22
in general payments reported to CMS, 2019-2025
17 companies · $551 in 2025
The $551 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.47 · 2021: $15.06 · 2022: $60.75 · 2023: $34.86 · 2024: $861 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412 · Education: $34.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.08 |
| Education | $34.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $418.28 | 2024-2025 | Enhertu, Imfinzi |
| Tempus Ai, INC | $232.57 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $149.69 | 2019-2025 | Opdivo |
| Eisai INC. | $145.14 | 2024 | |
| Genmab U.S., INC. | $123.35 | 2025 | Epkinly |
| Novartis Pharmaceuticals Corporation | $118.68 | 2024-2025 | |
| Genentech USA, INC. | $65.25 | 2022-2025 | Polivy |
| Pfizer INC. | $59.62 | 2023-2024 | |
| Janssen Biotech, INC. | $57.90 | 2019-2022 | |
| Celgene Corporation | $35.71 | 2024 | Reblozyl |
| Genentech, INC. | $35.34 | 2024 | Columvi, Lunsumio |
| Coherus Oncology, INC. | $31.95 | 2024 | |
| Tersera Therapeutics LLC | $31.71 | 2025 | Zoladex |
| Daiichi Sankyo INC. | $27.25 | 2025 | Enhertu |
| Merck Sharp & Dohme LLC | $26.14 | 2025 | Keytruda, Lynparza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $25.14 | 2024 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $18.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Macapinlac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.